Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forma To Play To Its Strengths WIth Genentech Deal

This article was originally published in Start Up

Executive Summary

Forma Therapeutics Inc.'s licensing agreement with Genentech Inc., announced June 27, is a creative twist on option-style dealmaking that could bring returns to the start-up's venture investors while skirting the traditional exit routes of acquisition and public offering. The deal illustrates one path highly innovative platform-focused biotechs could take when they are trying to satisfy the demands of venture backers while remaining focused on their strengths in early stage drug discovery.
Advertisement

Related Content

IND Over POC: The New Sweet Spot For Biopharma Dealmaking
Bridging The Gap Between Sell- And Buy- Sides In Biopharma Business Development
BMS' Purchase Of Amira: When An Acquisition Is Really An Asset Sale
Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model
Investing A La Carte: Making Separate Bets on Discovery and Development to Boost Near-Term Returns
Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model
Ablexis' Pharmaceutical Consortium
Biotechs Target Cancer Metabolism
Celgene Teams Up With Agios In Long-Term Cancer Metabolism Pact
Adimab Inks Merck, Roche Deals and Banks on the Value of Discovery

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092143

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel